Zim Laboratories Limited Stock Price Today (NSE: ZIMLAB)
Fundamental Score
Zim Laboratories Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Zim Laboratories Limited share price today is ₹136.78, up +2.37% on NSE/BSE as of 16 September 2026. Zim Laboratories Limited (ZIMLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹732.44 (Cr). The 52-week high for ZIMLAB share price is ₹144.49 and the 52-week low is ₹59.31. At a P/E ratio of 166.80x, ZIMLAB is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 2.13% and a debt-to-equity ratio of 0.42.
Zim Laboratories Limited Share Price Chart — NSE/BSE Historical Performance
Zim Laboratories Limited share price chart: 15.76% return over the past month. 52-week high ₹144.49, 52-week low ₹59.31.
Zim Laboratories Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹130.16 | ₹138.99 | ₹127.81 | ₹136.78 | 1.05L (Cr) | |
| ₹136.00 | ₹138.96 | ₹128.02 | ₹133.61 | 1.46L (Cr) | |
| ₹137.18 | ₹141.50 | ₹132.00 | ₹139.22 | 1.19L (Cr) | |
| ₹133.35 | ₹144.49 | ₹133.35 | ₹136.43 | 4.59L (Cr) | |
| ₹128.20 | ₹135.00 | ₹126.76 | ₹133.35 | 1.70L (Cr) | |
| ₹130.45 | ₹133.89 | ₹125.56 | ₹129.10 | 49.30K (Cr) | |
| ₹126.00 | ₹132.10 | ₹125.90 | ₹129.16 | 83.81K (Cr) | |
| ₹128.66 | ₹129.00 | ₹125.25 | ₹125.50 | 54.80K (Cr) | |
| ₹130.00 | ₹134.49 | ₹127.00 | ₹128.02 | 1.39L (Cr) | |
| ₹117.94 | ₹136.90 | ₹116.30 | ₹133.95 | 6.80L (Cr) |
Zim Laboratories Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹122.60 | ₹144.49 | ₹116.25 | ₹136.78 | +11.57% | |
| ₹108.50 | ₹130.40 | ₹107.10 | ₹122.69 | +13.08% | |
| ₹122.50 | ₹124.50 | ₹120.05 | ₹124.50 | +1.63% | |
| ₹106.00 | ₹133.90 | ₹99.06 | ₹124.00 | +16.98% | |
| ₹87.00 | ₹115.00 | ₹85.34 | ₹102.29 | +17.57% | |
| ₹61.30 | ₹89.89 | ₹61.30 | ₹87.94 | +43.46% | |
| ₹68.50 | ₹74.00 | ₹59.31 | ₹60.26 | -12.03% | |
| ₹71.14 | ₹79.80 | ₹67.91 | ₹69.75 | -1.95% | |
| ₹71.84 | ₹81.35 | ₹65.52 | ₹71.52 | -0.45% | |
| ₹72.66 | ₹76.00 | ₹67.25 | ₹72.15 | -0.70% | |
| ₹73.20 | ₹79.60 | ₹69.55 | ₹72.66 | -0.74% | |
| ₹71.74 | ₹82.71 | ₹67.00 | ₹73.24 | +2.09% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Zim Laboratories Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Zim Laboratories Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ZIMLAB across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (114.24%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (31.25%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
10 factors identified
Below-Average Return on Equity (2.13%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.54%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 166.80x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (4.03% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-18.53% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-16.98% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (1.62x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-16.66 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.07%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Zim Laboratories Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Zim Laboratories Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Zim Laboratories LimitedZim Laboratorie...Selected✓ ZIMLAB • 541400 | 3.5/100 | ₹136.78₹137 | ₹732.44₹732.44 | 166.80Average 166.8 Average | 2.13%Poor 2.13% Poor | 6.54%Poor 6.54% Poor | 0.42Excellent 0.4 Excellent | -16.98%Poor -16.98% Poor | 4.03%Average 4.03% Average | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Zim Laboratories Limited PE Ratio History
Historical price-to-earnings ratio for ZIMLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹2.50 | ₹72.15 | 28.9x |
| FY 2024 | ₹3.54 | ₹107.52 | 30.4x |
| FY 2023 | ₹5.01 | ₹115.35 | 23x |
| FY 2022 | ₹2.99 | ₹97.20 | 32.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Zim Laboratories Limited Dividend History
Annual cash dividends paid by ZIMLAB — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹0.06 Cr |
| FY 2024 | ₹0.05 Cr |
| FY 2023 | ₹0.06 Cr |
| FY 2022 | ₹0.17 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Zim Laboratories Limited Quarterly Performance
Latest quarterly metrics for ZIMLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
31.25%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
114.24%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
4.03%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-16.98%
Compounded annual net profit growth over 5 years
Zim Laboratories Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ZIMLAB — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Zim Laboratories Limited Financial Statements
Annual income statement, balance sheet and cash flow for Zim Laboratories Limited (ZIMLAB) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Zim Laboratories Limited
About ZIMLAB (Zim Laboratories Limited)
Zim Laboratories Ltd is a dynamic pharmaceutical entity focused on crafting innovative drug delivery solutions for a global market. With a strong emphasis on research and developme...nt, ZIMLAB formulates and manufactures a diverse range of pharmaceutical and nutraceutical products, aiming to enhance patient compliance and therapeutic outcomes. The company's dedication to quality and innovation is reflected in its state-of-the-art manufacturing facilities and adherence to stringent international regulatory standards. ZIMLAB leverages advanced technologies to develop specialized dosage forms, addressing unmet medical needs and improving the overall patient experience. Their mission is to provide high-quality, affordable healthcare solutions that make a positive impact on people's lives worldwide, driven by a commitment to excellence and ethical business practices. The core competency of Zim Laboratories lies in its ability to create and deliver specialized oral solid dosage forms. They excel in producing pellets, taste-masked formulations, and rapidly dissolving oral thin films, catering to patients with swallowing difficulties or specific therapeutic requirements. This includes developing formulations that mask unpleasant tastes, making medications more palatable and improving adherence, particularly among pediatric and geriatric populations. ZIMLAB's expertise extends to the development of dry syrups and customized granules, offering flexibility in dosing and administration. This focus on innovative drug delivery systems allows ZIMLAB to differentiate itself in the competitive pharmaceutical landscape, offering tailored solutions that address specific patient needs and improve the effectiveness of treatments. ZIMLAB's therapeutic focus spans a broad spectrum of medical areas, addressing prevalent health conditions across various demographics. The company develops and manufactures medications targeting urological disorders, gastrointestinal ailments, and infectious diseases. Their product portfolio also includes cardiovascular drugs and anti-infectives, reflecting a commitment to providing solutions for chronic and acute conditions. By strategically targeting these key therapeutic areas, ZIMLAB aims to contribute to improved patient outcomes and overall public health. The company's global reach ensures that these essential medications are accessible to patients in need, solidifying ZIMLAB's position as a reliable and impactful player in the pharmaceutical industry.
Company Details
Key Leadership
ZIMLAB Share Price: Frequently Asked Questions
What is the current share price of Zim Laboratories Limited?
Zim Laboratories Limited (ZIMLAB) trades at ₹136.78 on NSE and BSE. Market cap ₹732.44 (Cr). Educational data only.
What is the P/E ratio of Zim Laboratories Limited?
Zim Laboratories Limited has a P/E of 166.80x vs industry average 34.89x.
What is the Bull Run score for Zim Laboratories Limited?
Zim Laboratories Limited has a Bull Run score of 3.5/100 based on 25+ financial parameters.
Does Zim Laboratories Limited pay dividends?
Zim Laboratories Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Zim Laboratories Limited?
Zim Laboratories Limited has ROE of 2.13%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Zim Laboratories Limited?
Zim Laboratories Limited has debt-to-equity of 0.42.
Is Zim Laboratories Limited a good investment?
Bull Run gives Zim Laboratories Limited a score of 3.5/100. This is not investment advice — consult a SEBI-registered advisor.